News
-
Ena Respiratory (formerly Innavac) said that its INNA-051 pegylated TLR2/6 agonist nasal spray reduced replication of the SARS-CoV-2 virus in a ferret model by up to 96% in a study conducted by researchers at Public… Read more . . .
-
Inhalation CDMO Vectura has announced the resignation of Aerami CEO Anne Whitaker from Vectura’s board of directors “in light of potential conflicts that could arise in the future as a result of her role of… Read more . . .
-
Nasal spray CDMO Summit Biosciences has nearly completed a $19 million expansion of its facility at the University of Kentucky Coldstream Research Campus that is expected to create 78 jobs, the state of Kentucky has… Read more . . .
-
Galecto said that it has completed a $64 million equity financing led by Soleus Capital that will be used to advance several candidates, including GB0139, a galectin-3 inhibitor DPI for the treatment of idiopathic pulmonary… Read more . . .
-
TFF Pharmaceuticals is drawing attention to in vitro data published by researchers at the University of Texas Austin which found that thin film freezing “produces high potency remdesivir dry powder formulations for inhalation suitable to… Read more . . .
-
The FDA has granted orphan drug and rare pediatric disease designations to Spirovant Sciences’s SPIRO-2101, an inhaled adeno-associated virus (AAV) gene therapy for the treatment of cystic fibrosis, the company said. SPIRO-2101 works by replacing defective… Read more . . .
-
Bharat Biotech and Precision Virologics have acquired the rights to a single dose intranasal COVID-19 vaccine developed at the Washington University School of Medicine in St. Louis, the companies said. The agreement gives Precision Virologics… Read more . . .
-
Verona Pharma has announced the initiation of the Phase 3 ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) program to study the use of nebulized ensifentrine for the treatment of moderate to severe COPD.… Read more . . .
-
Neurelis has announced plans to conduct a clinical trial of Valtoco diazepam nasal spray in children with epilepsy aged 2-5 and said that the company intends to file an sNDA to expand the use of… Read more . . .
-
Recordati has acquired marketing rights to ARS Pharmaceuticals’ ARS-1 epinephrine nasal spray in the EU, Iceland, Liechtenstein, Norway, Switzerland, the UK, Russia/CIS, Turkey, the Middle East, and francophone African countries, the companies said. ARS will… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK